Drug Information

Drug General Information
Drug ID
D02PIO
Former ID
DNCL003376
Drug Name
Benralizumab
Drug Type
Monoclonal antibody
Indication Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10:J40-J44, J47, J45] Phase 3 [525153], [542653]
Asthma; Chronic obstructive pulmonary disease; Hypereosinophilic syndrome; asthma; Eosinophilic chronic rhinosinusitis [ICD10:D72.1, J40-J44, J45] Phase 1/2 [889397], [889422], [889428], [889429]
Company
GlaxoSmithKline
CAS Number
CAS 1044511-01-4
Target and Pathway
Target(s) Interleukin-5 Target Info Modulator
Interleukin-5 receptor subunit alpha Target Info Modulator [889445]
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
T cell receptor signaling pathway
Fc epsilon RI signaling pathway
Intestinal immune network for IgA production
Asthma
Autoimmune thyroid disease
Inflammatory bowel disease (IBD)
Allograft rejection
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
IL4-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Glucocorticoid receptor regulatory network
IL5-mediated signaling events
AP-1 transcription factor network
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways Cytokines and Inflammatory Response
Inflammatory Response Pathway
Hematopoietic Stem Cell Differentiation
Interleukin-2 signaling
Allograft Rejection
Interleukin-3, 5 and GM-CSF signaling
References
Ref 525153ClinicalTrials.gov (NCT02417961) Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home. U.S. National Institutes of Health.
Ref 542653(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
Ref 889397ClinicalTrials.gov (NCT02130882) Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Ref 889422ClinicalTrials.gov (NCT02772419) Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Ref 889428ClinicalTrials.gov (NCT02968914) Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
Ref 889429ClinicalTrials.gov (NCT03010436) Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Ref 889445Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.